Renal tumor pathology has evolved considerably, expanding from two main types of renal malignant tumors to over 20 distinct types.
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update – Biotech Investments
Issuer: CureVac / Key word(s): Quarterly / Interim Statement 14.11.2023 / 13:00 CET/CEST The issuer is solely responsible for the content of this announcement. CureVac